Skip to main content
Premium Trial:

Request an Annual Quote

Armed Forces to Use Calibrant's Gemini for Biomarker Research

NEW YORK (GenomeWeb News) – The Armed Forces Institute of Pathology will use Calibrant Biosystems’ Gemini proteomics platform to validate biomarkers for brain cancer and to discover other predictive markers, the company said today.
 
Under a Cooperative Research and Development Agreement, AFIP, which is part of the US Department of Defense, will produce custom tissue microarrays in agreement with Calibrant’s specifications. The collaboration will focus initially on brain cancer with the ultimate goal of identifying predictive markers for personalized medicine, said Calibrant.
 
The Gemini platform is compatible with fresh and formalin-fixed archival tissues, allowing users to map protein networks between different cell types within one tissue section.
 
Michael Salgaller, COO of Gaithersburg, Md.-based Calibrant, said in a statement that the AFIP partnership is “an excellent way to conduct high-throughput validation on a large population set of carefully chosen samples.”
 
Financial terms of the agreement were not released.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.